The path toward therapeutic psychedelic-based drugs is becoming clearer as scientists understand more about how they are processed in the body.
The serotonin 2A receptor is a major player in the psychedelic response, but it may not be the only one involved.
Despite differing pharmacodynamics, ketamine and serotonergic psychedelics may share downstream effects crucial to their rapid and sustained antidepressant activity.
This innovation may pave the way for pharmaceuticals that act like psychedelics at the 5-HT2A receptor but don’t have hallucinogenic effects.
The names may sound familiar, but these compounds reveal more about nature’s complex chemical cocktail in toad venom.
Ketamine and psilocybin both exert rapid antidepressant effects. Could these effects be explained by a common mechanism that promotes neurogenesis?
A recent study indicates that the empathogenic effects of LSD may be independent of serotonin 2A receptor activation.
Is DMT produced in the brain? The answer remains unclear, but this 2019 study provides striking evidence supporting the neural-DMT synthesis hypothesis.
Lenz et al. have revised their bluing theory based on the data from their new study.
Changes in structural neuroplasticity start within 24 hours, are enduring, and may not be solely dependent on 5-HT2A.